ID   RET_HUMAN               Reviewed;        1114 AA.
AC   P07949; Q15250; Q9H4A2;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 3.
DT   02-NOV-2010, entry version 156.
DE   RecName: Full=Proto-oncogene tyrosine-protein kinase receptor Ret;
DE            EC=2.7.10.1;
DE   AltName: Full=Cadherin family member 12;
DE   AltName: Full=Proto-oncogene c-Ret;
DE   Flags: Precursor;
GN   Name=RET; Synonyms=CDHF12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-280.
RX   MEDLINE=89282215; PubMed=2660074;
RA   Takahashi M.;
RT   "Isolation of ret proto-oncogene cDNA with an amino-terminal signal
RT   sequence.";
RL   Oncogene 4:805-806(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114.
RX   MEDLINE=90272230; PubMed=3078962;
RA   Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.;
RT   "Cloning and expression of the ret proto-oncogene encoding a tyrosine
RT   kinase with two potential transmembrane domains.";
RL   Oncogene 3:571-578(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063.
RX   MEDLINE=87257826; PubMed=3037315;
RA   Takahashi M., Cooper G.M.;
RT   "ret transforming gene encodes a fusion protein homologous to tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 7:1378-1385(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114, AND CHROMOSOMAL TRANSLOCATION
RP   WITH GOLGA5.
RC   TISSUE=Fibroblast;
RX   MEDLINE=89282212; PubMed=2734021;
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RT   "Activation of the ret-II oncogene without a sequence encoding a
RT   transmembrane domain and transforming activity of two ret-II oncogene
RT   products differing in carboxy-termini due to alternative splicing.";
RL   Oncogene 4:789-794(1989).
RN   [5]
RP   ERRATUM.
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RL   Oncogene 4:1415-1415(1989).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114, AND CHROMOSOMAL TRANSLOCATION
RP   WITH CCDC6.
RC   TISSUE=Thyroid papillary carcinoma;
RX   MEDLINE=90150283; PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3;
RA   Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R.,
RA   Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.;
RT   "PTC is a novel rearranged form of the ret proto-oncogene and is
RT   frequently detected in vivo in human thyroid papillary carcinomas.";
RL   Cell 60:557-563(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-770, AND CHROMOSOMAL TRANSLOCATION
RP   WITH PCM1.
RX   MEDLINE=20438683; PubMed=10980597; DOI=10.1038/sj.onc.1203772;
RA   Corvi R., Berger N., Balczon R., Romeo G.;
RT   "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.";
RL   Oncogene 19:4236-4242(2000).
RN   [8]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TIF1.
RX   MEDLINE=99367902; PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused
RT   to the RET receptor tyrosine kinase in childhood papillary thyroid
RT   carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [9]
RP   PHOSPHORYLATION AT TYR-1015 AND TYR-1062.
RX   MEDLINE=20513733; PubMed=11061555; DOI=10.1210/jc.85.10.3898;
RA   Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G.,
RA   Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.;
RT   "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret
RT   and ret-derived oncoproteins.";
RL   J. Clin. Endocrinol. Metab. 85:3898-3907(2000).
RN   [10]
RP   PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981;
RP   TYR-1015; TYR-1062; TYR-1090 AND TYR-1096.
RX   PubMed=14711813; DOI=10.1074/jbc.M312600200;
RA   Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R.,
RA   Kato M., Suzuki H., Takahashi M., Nakashima I.;
RT   "Identification of RET autophosphorylation sites by mass
RT   spectrometry.";
RL   J. Biol. Chem. 279:14213-14224(2004).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH RFP.
RX   MEDLINE=22672949; PubMed=12787916; DOI=10.1016/S0027-5107(03)00056-3;
RA   Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A.,
RA   Lushnikov E., Roumiantsev P., Matsumoto N., Nakashima M.,
RA   Meirmanov S., Ohtsuru A., Namba H., Tsyb A., Yamashita S.;
RT   "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary
RT   thyroid carcinoma from externally irradiated patient.";
RL   Mutat. Res. 527:81-90(2003).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX
RP   WITH INHIBITORS, MASS SPECTROMETRY, AND PHOSPHORYLATION AT TYR-900 AND
RP   TYR-905.
RX   PubMed=16928683; DOI=10.1074/jbc.M605604200;
RA   Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S.,
RA   Santoro M., Ibanez C.F., McDonald N.Q.;
RT   "Structure and chemical inhibition of the RET tyrosine kinase
RT   domain.";
RL   J. Biol. Chem. 281:33577-33587(2006).
RN   [14]
RP   REVIEW ON HSCR VARIANTS.
RX   MEDLINE=98023959; PubMed=9359036;
RA   Hofstra R.M.W., Osinga J., Buys C.H.C.M.;
RT   "Mutations in Hirschsprung disease: when does a mutation contribute to
RT   the phenotype.";
RL   Eur. J. Hum. Genet. 5:180-185(1997).
RN   [15]
RP   REVIEW ON VARIANTS.
RX   MEDLINE=97220587; PubMed=9067749;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q;
RA   Eng C., Mulligan L.M.;
RT   "Mutations of the RET proto-oncogene in the multiple endocrine
RT   neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung
RT   disease.";
RL   Hum. Mutat. 9:97-109(1997).
RN   [16]
RP   VARIANTS MEN2A/MTC TRP-611; SER-618; ARG-620; TYR-620 AND ARG-634.
RX   MEDLINE=93372843; PubMed=8103403; DOI=10.1093/hmg/2.7.851;
RA   Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K.,
RA   Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.;
RT   "Mutations in the RET proto-oncogene are associated with MEN 2A and
RT   FMTC.";
RL   Hum. Mol. Genet. 2:851-856(1993).
RN   [17]
RP   VARIANTS MEN2A GLY-618; 632-ASP--ARG-634; GLY-634; PHE-634; TYR-634
RP   AND SER-634.
RX   MEDLINE=93275414; PubMed=8099202; DOI=10.1038/363458a0;
RA   Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C.,
RA   Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A.,
RA   Telenius H., Tunnacliffe A., Ponder B.A.J.;
RT   "Germ-line mutations of the RET proto-oncogene in multiple endocrine
RT   neoplasia type 2A.";
RL   Nature 363:458-460(1993).
RN   [18]
RP   VARIANTS HSCR PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND
RP   LEU-973.
RX   MEDLINE=95219414; PubMed=7704557;
RA   Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I.,
RA   Pasini B., Tocco T., Lerone M., Cywes S., Moore S.,
RA   Vanderwinden J.-M., Abramowicz M.J., Kristoffersson U., Larsson L.T.,
RA   Hamel B.C.J., Silengo M., Martucciello G., Romeo G.;
RT   "Heterogeneity and low detection rate of RET mutations in Hirschsprung
RT   disease.";
RL   Eur. J. Hum. Genet. 2:272-280(1994).
RN   [19]
RP   VARIANT MEN2B THR-918.
RX   MEDLINE=94272459; PubMed=7911697; DOI=10.1093/hmg/3.2.237;
RA   Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S.,
RA   Ponder M.A., Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A.,
RA   Ponder B.A.J.;
RT   "Point mutation within the tyrosine kinase domain of the RET proto-
RT   oncogene in multiple endocrine neoplasia type 2B and related sporadic
RT   tumours.";
RL   Hum. Mol. Genet. 3:237-241(1994).
RN   [20]
RP   VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634;
RP   GLY-634 AND TYR-634.
RX   MEDLINE=94348513; PubMed=7915165; DOI=10.1093/hmg/3.4.635;
RA   Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N.,
RA   Schuster M.K., Browden D.W., Mao J.-I., Noll W.W.;
RT   "Germline RET mutations in MEN 2A and FMTC and their detection by
RT   simple DNA diagnostic tests.";
RL   Hum. Mol. Genet. 3:635-638(1994).
RN   [21]
RP   VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620.
RX   MEDLINE=95152521; PubMed=7849720; DOI=10.1093/hmg/3.10.1895;
RA   Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B.,
RA   Hruban R.H., Sidransky D.;
RT   "RET proto-oncogene mutations in inherited and sporadic medullary
RT   thyroid cancer.";
RL   Hum. Mol. Genet. 3:1895-1897(1994).
RN   [22]
RP   VARIANTS MTC, AND VARIANTS MEN2A.
RX   MEDLINE=95179108; PubMed=7874109; DOI=10.1093/hmg/3.11.1939;
RA   Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N.,
RA   Calmettes C., Modigliani E., Lenoir G.M.;
RT   "RET proto-oncogene mutations in French MEN 2A and FMTC families.";
RL   Hum. Mol. Genet. 3:1939-1943(1994).
RN   [23]
RP   VARIANT HSCR TRP-609, VARIANT HSCR/MEN2A ARG-618, AND VARIANT HSCR/MTC
RP   ARG-620.
RX   MEDLINE=95187155; PubMed=7881414; DOI=10.1093/hmg/3.12.2163;
RA   Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J.,
RA   Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A.,
RA   Venter D.J., Munnich A., Ponder B.A.J.;
RT   "Diverse phenotypes associated with exon 10 mutations of the RET
RT   proto-oncogene.";
RL   Hum. Mol. Genet. 3:2163-2167(1994).
RN   [24]
RP   VARIANT MEN2B THR-918.
RX   MEDLINE=94159102; PubMed=7906866; DOI=10.1038/367375a0;
RA   Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P.,
RA   Stelwagen T., Luo Y., Pasini B., Hoeppener J.W.M.,
RA   Ploos van Amstel H.K., Romeo G., Lips C.J.M., Buys C.H.C.M.;
RT   "A mutation in the RET proto-oncogene associated with multiple
RT   endocrine neoplasia type 2B and sporadic medullary thyroid
RT   carcinoma.";
RL   Nature 367:375-376(1994).
RN   [25]
RP   VARIANTS HSCR PRO-765; GLN-897 AND GLY-972.
RX   MEDLINE=94159103; PubMed=8114938; DOI=10.1038/367377a0;
RA   Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I.,
RA   Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.;
RT   "Point mutations affecting the tyrosine kinase domain of the RET
RT   proto-oncogene in Hirschsprung's disease.";
RL   Nature 367:377-378(1994).
RN   [26]
RP   VARIANTS HSCR LEU-32; LEU-64; GLN-330 AND LEU-393.
RX   MEDLINE=94159104; PubMed=8114939; DOI=10.1038/367378a0;
RA   Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L.,
RA   Holder S., Nihoul-Fkete C., Ponder B.A.J., Munnich A.;
RT   "Mutations of the RET proto-oncogene in Hirschsprung's disease.";
RL   Nature 367:378-380(1994).
RN   [27]
RP   VARIANT MEN2B THR-918.
RX   MEDLINE=94151373; PubMed=7906417; DOI=10.1073/pnas.91.4.1579;
RA   Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E.,
RA   Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.;
RT   "Single missense mutation in the tyrosine kinase catalytic domain of
RT   the RET protooncogene is associated with multiple endocrine neoplasia
RT   type 2B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994).
RN   [28]
RP   VARIANTS MTC; MEN2A AND MEN2B.
RX   MEDLINE=96223053; PubMed=8625130;
RX   DOI=10.1002/1097-0142(19950801)76:3<479::AID-CNCR2820760319>3.0.CO;2-M;
RA   Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G.,
RA   Colomer A., Roth J., Heitz P.U.;
RT   "Analysis of RET protooncogene point mutations distinguishes heritable
RT   from nonheritable medullary thyroid carcinomas.";
RL   Cancer 76:479-489(1995).
RN   [29]
RP   VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634.
RX   MEDLINE=95163936; PubMed=7860065; DOI=10.1007/BF00209399;
RA   Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S.,
RA   Takami H., Hikiji K., Nakamura Y.;
RT   "Germline mutations of the RET proto-oncogene in eight Japanese
RT   patients with multiple endocrine neoplasia type 2A (MEN2A).";
RL   Hum. Genet. 95:187-190(1995).
RN   [30]
RP   VARIANTS HSCR LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND
RP   VARIANT CYS-982.
RC   TISSUE=Blood;
RX   MEDLINE=95360000; PubMed=7633441; DOI=10.1093/hmg/4.5.821;
RA   Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W.,
RA   Buys C.H.C.M., Cass D.T., Chakravarti A.;
RT   "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung
RT   disease.";
RL   Hum. Mol. Genet. 4:821-830(1995).
RN   [31]
RP   VARIANTS HSCR.
RC   TISSUE=Leukocyte;
RX   MEDLINE=96090258; PubMed=7581377; DOI=10.1093/hmg/4.8.1381;
RA   Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J.,
RA   Boutrand L., Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J.,
RA   Lyonnet S.;
RT   "Diversity of RET proto-oncogene mutations in familial and sporadic
RT   Hirschsprung disease.";
RL   Hum. Mol. Genet. 4:1381-1386(1995).
RN   [32]
RP   VARIANT MEN2B THR-918, AND VARIANT TYR-922.
RX   MEDLINE=96121602; PubMed=8595427; DOI=10.1093/hmg/4.10.1987;
RA   Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E.,
RA   Goodfellow P.J.;
RT   "Two maternally derived missense mutations in the tyrosine kinase
RT   domain of the RET protooncogene in a patient with de novo MEN 2B.";
RL   Hum. Mol. Genet. 4:1987-1988(1995).
RN   [33]
RP   VARIANT MTC ASP-768.
RX   MEDLINE=95148221; PubMed=7845675;
RA   Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J.,
RA   Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D.,
RA   Ponder B.A.J.;
RT   "A novel point mutation in the tyrosine kinase domain of the RET
RT   proto-oncogene in sporadic medullary thyroid carcinoma and in a family
RT   with FMTC.";
RL   Oncogene 10:509-513(1995).
RN   [34]
RP   VARIANTS MTC ASP-768 AND LEU-804.
RX   MEDLINE=95303511; PubMed=7784092;
RA   Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T.,
RA   Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J.,
RA   Lenoir G.M., Romeo G.;
RT   "RET mutations in exons 13 and 14 of FMTC patients.";
RL   Oncogene 10:2415-2419(1995).
RN   [35]
RP   VARIANTS HSCR TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND
RP   PRO-1061.
RA   Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C.,
RA   Buys C.H.C.M.;
RT   "Mutations in three genes are found associated with the development of
RT   Hirschsprung disease: RET, EDNRB and EDN3.";
RL   Am. J. Hum. Genet. 59:A263-A263(1996).
RN   [36]
RP   VARIANTS HSCR PRO-40 AND PRO-765.
RX   MEDLINE=97196781; PubMed=9043870;
RA   Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.;
RT   "Prevalence and parental origin of de novo RET mutations in
RT   Hirschsprung's disease.";
RL   Eur. J. Hum. Genet. 4:356-358(1996).
RN   [37]
RP   VARIANTS MTC/MEN2A.
RX   MEDLINE=96140742; PubMed=8557249; DOI=10.1007/BF00218825;
RA   Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M.,
RA   Lips C.J.M., van Amstel H.K.P.;
RT   "Mutation analysis of the RET proto-oncogene in Dutch families with
RT   MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation
RT   for MEN 2A.";
RL   Hum. Genet. 97:11-14(1996).
RN   [38]
RP   VARIANTS MEN2A, VARIANT MTC ASP-768, AND VARIANT MEN2B THR-918.
RX   MEDLINE=96400962; PubMed=8807338;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:1<64::AID-HUMU9>3.3.CO;2-N;
RA   Kambouris M., Jackson C.E., Feldman G.L.;
RT   "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial
RT   medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex
RT   analyses of RET proto-oncogene mutations.";
RL   Hum. Mutat. 8:64-70(1996).
RN   [39]
RP   VARIANTS MEN2A.
RX   MEDLINE=96210855; PubMed=8626834; DOI=10.1210/jc.81.5.1780;
RA   Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H.,
RA   Haase R., Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F.,
RA   Ritter M.M., Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U.,
RA   Brabant G., Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J.,
RA   Doerr A.G., Hoehne T., Hoernig-Franz I., Huefner M., Kress J.,
RA   Langer H.J., Lottermoser K., Schweikert H.U., Kusterer K., Menken U.,
RA   Mercier J., Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.;
RT   "Mutations of the ret protooncogene in German multiple endocrine
RT   neoplasia families: relation between genotype and phenotype.";
RL   J. Clin. Endocrinol. Metab. 81:1780-1783(1996).
RN   [40]
RP   VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS.
RX   MEDLINE=97252394; PubMed=9097963; DOI=10.1093/hmg/6.4.587;
RA   Hoeppner W., Ritter M.M.;
RT   "A duplication of 12 bp in the critical cysteine rich domain of the
RT   RET proto-oncogene results in a distinct phenotype of multiple
RT   endocrine neoplasia type 2A.";
RL   Hum. Mol. Genet. 6:587-590(1997).
RN   [41]
RP   VARIANTS HSCR PRO-180; GLN-313; ARG-620 AND PHE-791.
RX   MEDLINE=97245887; PubMed=9090527;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:3<243::AID-HUMU5>3.3.CO;2-N;
RA   Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R.,
RA   Pasini B., Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T.,
RA   Casasa J.M., Cass D.T., Abramowicz M.J., Vanderwinden J.-M.,
RA   Kravcenkiene I., Baric I., Silengo M., Martucciello G., Romeo G.;
RT   "Frequency of RET mutations in long- and short-segment Hirschsprung
RT   disease.";
RL   Hum. Mutat. 9:243-249(1997).
RN   [42]
RP   VARIANT MTC/HSCR ARG-618.
RX   MEDLINE=97403937; PubMed=9259198;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:2<155::AID-HUMU7>3.3.CO;2-G;
RA   Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S.,
RA   Grynberg E., Yakobson E., Graff E., Lapidot M.;
RT   "Cys 618 Arg mutation in the RET proto-oncogene associated with
RT   familial medullary thyroid carcinoma and maternally transmitted
RT   Hirschsprung's disease suggesting a role for imprinting.";
RL   Hum. Mutat. 10:155-159(1997).
RN   [43]
RP   VARIANT MEN2B PHE-883.
RC   TISSUE=Peripheral blood leukocyte;
RX   MEDLINE=98025012; PubMed=9360560; DOI=10.1210/jc.82.11.3902;
RA   Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M.,
RA   Mulligan L.M., Zajac J.D., Robinson B.G., Eng C.;
RT   "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene
RT   in multiple endocrine neoplasia type 2B without codon 918 mutation.";
RL   J. Clin. Endocrinol. Metab. 82:3902-3904(1997).
RN   [44]
RP   VARIANT MTC ALA-891.
RX   MEDLINE=98060982; PubMed=9398735; DOI=10.1210/jc.82.12.4176;
RA   Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U.,
RA   Colantuoni V., Buys C.H.C.M.;
RT   "A novel point mutation in the intracellular domain of the ret
RT   protooncogene in a family with medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 82:4176-4178(1997).
RN   [45]
RP   VARIANTS HSCR SER-174 AND TYR-197.
RX   MEDLINE=97247905; PubMed=9094028; DOI=10.1016/S0022-3468(97)90616-3;
RA   Kusafuka T., Wang Y., Puri P.;
RT   "Mutation analysis of the RET, the endothelin-B receptor, and the
RT   endothelin-3 genes in sporadic cases of Hirschsprung's disease.";
RL   J. Pediatr. Surg. 32:501-504(1997).
RN   [46]
RP   VARIANTS MTC; MEN2A AND MEN2B, AND VARIANT SER-691.
RX   MEDLINE=97366845; PubMed=9223675; DOI=10.1038/sj.onc.1201102;
RA   Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K.,
RA   Kitagawa W., Akasu H., Takami H., Tanaka S., Wells S.A. Jr.;
RT   "Novel germline RET proto-oncogene mutations associated with medullary
RT   thyroid carcinoma (MTC): mutation analysis in Japanese patients with
RT   MTC.";
RL   Oncogene 14:3103-3106(1997).
RN   [47]
RP   VARIANT MEN2B PHE-883.
RX   MEDLINE=97440308; PubMed=9294615; DOI=10.1038/sj.onc.1201481;
RA   Smith D.P., Houghton C., Ponder B.A.J.;
RT   "Germline mutation of RET codon 883 in two cases of de novo MEN 2B.";
RL   Oncogene 15:1213-1217(1997).
RN   [48]
RP   VARIANT CCHS LEU-1039, AND VARIANT SER-691.
RX   MEDLINE=98163458; PubMed=9497256; DOI=10.1086/301759;
RA   Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M.,
RA   Gaultier C., Munnich A., Lyonnet S.;
RT   "Mutations of the RET-GDNF signaling pathway in Ondine's curse.";
RL   Am. J. Hum. Genet. 62:715-717(1998).
RN   [49]
RP   VARIANT MTC GLY-611.
RX   MEDLINE=98339719; PubMed=9677065;
RX   DOI=10.1002/(SICI)1096-8628(19980707)78:3<271::AID-AJMG13>3.0.CO;2-C;
RA   Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V.,
RA   Rivera-Fillat F.;
RT   "Novel point mutation in exon 10 of the RET proto-oncogene in a family
RT   with medullary thyroid carcinoma.";
RL   Am. J. Med. Genet. 78:271-273(1998).
RN   [50]
RP   VARIANT CYS-982.
RX   MEDLINE=98430996; PubMed=9760196; DOI=10.1007/s004390050797;
RA   Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.;
RT   "Phenotypic variation in a family with mutations in two Hirschsprung-
RT   related genes (RET and endothelin receptor B).";
RL   Hum. Genet. 103:145-148(1998).
RN   [51]
RP   VARIANTS MEN2A/HSCR TYR-609; SER-618; ARG-620 AND TRP-620.
RX   MEDLINE=98046016; PubMed=9384613; DOI=10.1093/hmg/7.1.129;
RA   Decker R.A., Peacock M.L., Watson P.;
RT   "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10
RT   genotypes and strong genotype-phenotype correlation.";
RL   Hum. Mol. Genet. 7:129-134(1998).
RN   [52]
RP   VARIANT MEN2A CYS-ARG-THR-636 INS.
RX   MEDLINE=98112443; PubMed=9452064;
RA   Hoeppner W., Dralle H., Brabant G.;
RT   "Duplication of 9 base pairs in the critical cysteine-rich domain of
RT   the RET proto-oncogene causes multiple endocrine neoplasia type 2A.";
RL   Hum. Mutat. Suppl. 1:S128-S130(1998).
RN   [53]
RP   VARIANT MTC MET-804.
RX   MEDLINE=98112456; PubMed=9452077;
RA   Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E.,
RA   Colantuoni V.;
RT   "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET
RT   proto-oncogene in two families affected by familial medullary thyroid
RT   carcinoma.";
RL   Hum. Mutat. Suppl. 1:S167-S171(1998).
RN   [54]
RP   VARIANTS MTC/MEN2A PHE-790 AND PHE-791.
RX   MEDLINE=98165568; PubMed=9506724; DOI=10.1210/jc.83.3.770;
RA   Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P.,
RA   Grussendorf M., Raue F., Ritter M.M., Hoeppner W.;
RT   "A new hot spot for mutations in the ret protooncogene causing
RT   familial medullary thyroid carcinoma and multiple endocrine neoplasia
RT   type 2A.";
RL   J. Clin. Endocrinol. Metab. 83:770-774(1998).
RN   [55]
RP   VARIANTS MTC AND MEN2A.
RX   MEDLINE=98284533; PubMed=9621513; DOI=10.1007/s100380050048;
RA   Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A.,
RA   Nakamura Y.;
RT   "Mutational analysis of the RET proto-oncogene in 71 Japanese patients
RT   with medullary thyroid carcinoma.";
RL   J. Hum. Genet. 43:101-106(1998).
RN   [56]
RP   VARIANTS HSCR LYS-626 AND GLN-813.
RX   MEDLINE=99192369; PubMed=10090908; DOI=10.1086/302329;
RA   Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A.,
RA   Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A.,
RA   Ceccherini I.;
RT   "Double heterozygosity for a RET substitution interfering with
RT   splicing and an EDNRB missense mutation in Hirschsprung disease.";
RL   Am. J. Hum. Genet. 64:1216-1221(1999).
RN   [57]
RP   VARIANTS HSCR ASN-1059 DEL AND PRO-1061.
RX   MEDLINE=99415738; PubMed=10484767; DOI=10.1093/hmg/8.11.1989;
RA   Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S.,
RA   Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.;
RT   "Two distinct mutations of the RET receptor causing Hirschsprung's
RT   disease impair the binding of signalling effectors to a
RT   multifunctional docking site.";
RL   Hum. Mol. Genet. 8:1989-1999(1999).
RN   [58]
RP   VARIANT MTC GLU-GLU-CYS-531 INS.
RX   MEDLINE=99254982; PubMed=10323403; DOI=10.1210/jc.84.5.1700;
RA   Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P.,
RA   Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.;
RT   "A novel 9-base pair duplication in RET exon 8 in familial medullary
RT   thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:1700-1704(1999).
RN   [59]
RP   VARIANT MEN2A GLY-640.
RX   MEDLINE=99450824; PubMed=10522989; DOI=10.1210/jc.84.10.3522;
RA   Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D.,
RA   Bellastella A., Colantuoni V.;
RT   "A novel case of multiple endocrine neoplasia type 2A associated with
RT   two de novo mutations of the RET protooncogene.";
RL   J. Clin. Endocrinol. Metab. 84:3522-3527(1999).
RN   [60]
RP   VARIANTS MTC MET-804 AND LEU-844.
RX   MEDLINE=20284753; PubMed=10826520; DOI=10.1055/s-2000-5806;
RA   Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.;
RT   "A RET double mutation in the germline of a kindred with FMTC.";
RL   Exp. Clin. Endocrinol. Diabetes 108:128-132(2000).
RN   [61]
RP   VARIANT GLN-600.
RX   MEDLINE=20081080; PubMed=10612852;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<122::AID-HUMU41>3.0.CO;2-7;
RA   Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G.,
RA   Borrego S.;
RT   "A new germline mutation, R600Q, within the coding region of RET
RT   proto-oncogene: a rare polymorphism or a MEN 2 causing mutation?";
RL   Hum. Mutat. 15:122-122(2000).
RN   [62]
RP   VARIANTS HSCR LEU-32; CYS-77; TRP-360 AND LYS-394.
RX   MEDLINE=20087238; PubMed=10618407; DOI=10.1073/pnas.97.1.268;
RA   Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D.,
RA   Buys C.H.C.M., Lyonnet S., Chakravarti A.;
RT   "A human model for multigenic inheritance: phenotypic expression in
RT   Hirschsprung disease requires both the RET gene and a new 9q31
RT   locus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000).
RN   [63]
RP   VARIANTS MTC GLY-639; GLY-641 AND PHE-922.
RX   MEDLINE=21550045; PubMed=11692159; DOI=10.1007/s001090100250;
RA   Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N.,
RA   Hosch S.B., Garkavtseva R.F., Izbicki J.R.;
RT   "Three novel mutations in the RET proto-oncogene.";
RL   J. Mol. Med. 79:609-612(2001).
RN   [64]
RP   VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634;
RP   TRP-634 AND PHE-791.
RX   PubMed=12000816; DOI=10.1056/NEJMoa020152;
RG   The Freiburg-Warsaw-Columbus pheochromocytoma study group;
RA   Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O.,
RA   Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K.,
RA   Januszewicz A., Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W.,
RA   Treier M., Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M.,
RA   Klein-Franke A., Klose P., Schmidt H., Maier-Woelfle M.,
RA   Peczkowska M., Szmigielski C., Eng C.;
RT   "Germ-line mutations in nonsyndromic pheochromocytoma.";
RL   N. Engl. J. Med. 346:1459-1466(2002).
RN   [65]
RP   VARIANT CCHS HIS-114.
RX   MEDLINE=22080693; PubMed=12086152; DOI=10.1620/tjem.196.241;
RA   Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K.,
RA   Hashimoto M., Hasegawa H., Shirasawa S., Hayasaka K.;
RT   "Congenital central hypoventilation syndrome: a novel mutation of the
RT   RET gene in an isolated case.";
RL   Tohoku J. Exp. Med. 196:241-246(2002).
RN   [66]
RP   VARIANTS ASN-489; SER-691 AND CYS-982, AND VARIANTS CCHS HIS-67;
RP   HIS-114 AND GLU-432.
RX   MEDLINE=22982299; PubMed=14566559; DOI=10.1007/s00439-003-1036-z;
RA   Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H.,
RA   Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W.,
RA   Nakamura T., Hayasaka K.;
RT   "Molecular analysis of congenital central hypoventilation syndrome.";
RL   Hum. Genet. 114:22-26(2003).
RN   [67]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [68]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489;
RP   SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [69]
RP   VARIANTS RENAL ADYSPLASIA THR-198; ALA-376; HIS-394; ILE-778; SER-894;
RP   THR-918; LEU-1049 AND SER-1067, AND CHARACTERIZATION OF VARIANTS RENAL
RP   ADYSPLASIA THR-198; ALA-376; HIS-394; ILE-778; SER-894; LEU-1049 AND
RP   SER-1067.
RX   PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008;
RA   Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E.,
RA   Freemerman A.J.;
RT   "Renal aplasia in humans is associated with RET mutations.";
RL   Am. J. Hum. Genet. 82:344-351(2008).
CC   -!- FUNCTION: Probable receptor with tyrosine-protein kinase activity;
CC       important for development.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Phosphorylated form interacts with the PBT domain of
CC       DOK2, DOK4 and DOK5 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Autophosphorylated on C-terminal tyrosine residues upon
CC       ligand stimulation.
CC   -!- POLYMORPHISM: The Cys-982 polymorphism may be associated with an
CC       increased risk for developing Hirschsprung disease.
CC   -!- DISEASE: Defects in RET may be a cause of colorectal cancer (CRC)
CC       [MIM:114500].
CC   -!- DISEASE: Defects in RET are a cause of Hirschsprung disease (HSCR)
CC       [MIM:142623]. HSCR is a genetic disorder of neural crest
CC       development characterized by the absence of intramural ganglion
CC       cells in the hindgut, often resulting in intestinal obstruction.
CC       Occasionally, MEN2A or FMTC occur in association with HSCR.
CC   -!- DISEASE: Defects in RET are the cause of medullary thyroid
CC       carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the
CC       C cells of the thyroid. Three hereditary forms are known, that are
CC       transmitted in an autosomal dominant fashion: (a) multiple
CC       neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B)
CC       and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases
CC       and where MTC is the only clinical manifestation.
CC   -!- DISEASE: Defects in RET are the cause of multiple neoplasia type
CC       2B (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer
CC       syndrome characterized by predisposition to MTC and
CC       phaeochromocytoma which is associated with marfanoid habitus,
CC       mucosal neuromas, skeletal and ophtalmic abnormalities, and
CC       ganglioneuromas of the intestine tract. Then the disease
CC       progresses rapidly with the development of metastatic MTC and a
CC       pheochromocytome in 50% of cases.
CC   -!- DISEASE: Defects in RET are a cause of susceptibility to
CC       pheochromocytoma (PCC) [MIM:171300]. A catecholamine-producing
CC       tumor of chromaffin tissue of the adrenal medulla or sympathetic
CC       paraganglia. The cardinal symptom, reflecting the increased
CC       secretion of epinephrine and norepinephrine, is hypertension,
CC       which may be persistent or intermittent.
CC   -!- DISEASE: Defects in RET are the cause of multiple neoplasia type
CC       2A (MEN2A) [MIM:171400]; also known as multiple neoplasia type 2
CC       (MEN2). MEN2A is the most frequent form of medullary thyroid
CC       cancer (MTC). It is an inherited cancer syndrome characterized by
CC       MTC, phaeochromocytoma and/or hyperparathyroidism.
CC   -!- DISEASE: Defects in RET are a cause of thyroid papillary carcinoma
CC       (TPC) [MIM:188550]. TPC is a common tumor of the thyroid that
CC       typically arises as an irregular, solid or cystic mass from
CC       otherwise normal thyroid tissue. Papillary carcinomas are
CC       malignant neoplasm characterized by the formation of numerous,
CC       irregular, finger-like projections of fibrous stroma that is
CC       covered with a surface layer of neoplastic epithelial cells.
CC       Note=Chromosomal aberrations involving RET are found in thyroid
CC       papillary carcinomas. Inversion inv(10)(q11.2;q21) generates the
CC       RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2)
CC       generates the RET/NCOA4 (PTC3) oncogene; translocation
CC       t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5)
CC       oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates
CC       the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP
CC       generates the Delta RFP/RET oncogene; translocation
CC       t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7)
CC       oncogene; translocation t(7;10)(q32;q11) with TIF1 generates the
CC       TIF1/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2
CC       cases of PACT in children exposed to radioactive fallout after
CC       Chernobyl.
CC   -!- DISEASE: Defects in RET are a cause of renal adysplasia
CC       [MIM:191830]; also known as renal agenesis or renal aplasia. Renal
CC       agenesis refers to the absence of one (unilateral) or both
CC       (bilateral) kidneys at birth. Bilateral renal agenesis belongs to
CC       a group of perinatally lethal renal diseases, including severe
CC       bilateral renal dysplasia, unilateral renal agenesis with
CC       contralateral dysplasia and severe obstructive uropathy.
CC   -!- DISEASE: Defects in RET are a cause of congenital central
CC       hypoventilation syndrome (CCHS) [MIM:209880]; also known as
CC       congenital failure of autonomic control or Ondine curse. CCHS is a
CC       rare disorder characterized by abnormal control of respiration in
CC       the absence of neuromuscular or lung disease, or an identifiable
CC       brain stem lesion. A deficiency in autonomic control of
CC       respiration results in inadequate or negligible ventilatory and
CC       arousal responses to hypercapnia and hypoxemia.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family.
CC   -!- SIMILARITY: Contains 1 cadherin domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36524.1; Type=Erroneous initiation;
CC       Sequence=CAA33787.1; Type=Erroneous initiation;
CC       Sequence=CAC14882.1; Type=Erroneous initiation;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RETID76.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/RET";
CC   -!- WEB RESOURCE: Name=MEN2 RET database;
CC       URL="http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X15262; CAA33333.1; -; mRNA.
DR   EMBL; X12949; CAA31408.1; -; mRNA.
DR   EMBL; M16029; AAA36786.1; ALT_SEQ; mRNA.
DR   EMBL; X15786; CAA33787.1; ALT_INIT; mRNA.
DR   EMBL; M31213; AAA36524.1; ALT_INIT; mRNA.
DR   EMBL; AJ297349; CAC14882.1; ALT_INIT; mRNA.
DR   IPI; IPI00013983; -.
DR   PIR; A27203; TVHURE.
DR   PIR; A34630; A34630.
DR   PIR; B34735; B34735.
DR   PIR; S05582; S05582.
DR   RefSeq; NP_065681.1; -.
DR   RefSeq; NP_066124.1; -.
DR   UniGene; Hs.350321; -.
DR   PDB; 1XPD; Model; -; A=709-1013.
DR   PDB; 2IVS; X-ray; 2.00 A; A/B=705-1013.
DR   PDB; 2IVT; X-ray; 2.60 A; A=705-1013.
DR   PDB; 2IVU; X-ray; 2.50 A; A=705-1013.
DR   PDB; 2IVV; X-ray; 2.25 A; A=705-1013.
DR   PDB; 2X2K; X-ray; 2.60 A; A=705-1013.
DR   PDB; 2X2L; X-ray; 2.00 A; A=705-1013.
DR   PDB; 2X2M; X-ray; 2.50 A; A/B=705-1013.
DR   PDB; 2X2U; X-ray; 2.00 A; A=29-270.
DR   PDBsum; 1XPD; -.
DR   PDBsum; 2IVS; -.
DR   PDBsum; 2IVT; -.
DR   PDBsum; 2IVU; -.
DR   PDBsum; 2IVV; -.
DR   PDBsum; 2X2K; -.
DR   PDBsum; 2X2L; -.
DR   PDBsum; 2X2M; -.
DR   PDBsum; 2X2U; -.
DR   ProteinModelPortal; P07949; -.
DR   MINT; MINT-265342; -.
DR   STRING; P07949; -.
DR   PhosphoSite; P07949; -.
DR   PRIDE; P07949; -.
DR   Ensembl; ENST00000355710; ENSP00000347942; ENSG00000165731.
DR   GeneID; 5979; -.
DR   KEGG; hsa:5979; -.
DR   UCSC; uc001jal.1; human.
DR   CTD; 5979; -.
DR   GeneCards; GC10P043572; -.
DR   HGNC; HGNC:9967; RET.
DR   HPA; CAB002581; -.
DR   HPA; CAB018342; -.
DR   HPA; HPA008356; -.
DR   MIM; 114500; phenotype.
DR   MIM; 142623; phenotype.
DR   MIM; 155240; phenotype.
DR   MIM; 162300; phenotype.
DR   MIM; 164761; gene.
DR   MIM; 171300; phenotype.
DR   MIM; 171400; phenotype.
DR   MIM; 188550; phenotype.
DR   MIM; 191830; phenotype.
DR   MIM; 209880; phenotype.
DR   Orphanet; 93173; Bilateral renal dysplasia.
DR   Orphanet; 388; Hirschsprung disease.
DR   Orphanet; 1332; Medullary thyroid carcinoma.
DR   Orphanet; 653; Multiple endocrine neoplasia type 2.
DR   Orphanet; 661; Ondine syndrome.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   Orphanet; 93172; Unilateral renal dysplasia.
DR   PharmGKB; PA34335; -.
DR   eggNOG; prNOG12621; -.
DR   HOGENOM; HBG444015; -.
DR   HOVERGEN; HBG002609; -.
DR   InParanoid; P07949; -.
DR   OMA; GCARVYF; -.
DR   OrthoDB; EOG9GTP0B; -.
DR   PhylomeDB; P07949; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; ret_pathway; Signaling events regulated by Ret tyrosine kinase.
DR   DrugBank; DB01268; Sunitinib.
DR   NextBio; 23271; -.
DR   ArrayExpress; P07949; -.
DR   Bgee; P07949; -.
DR   CleanEx; HS_RET; -.
DR   Genevestigator; P07949; -.
DR   GermOnline; ENSG00000165731; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kin...; IEA:EC.
DR   GO; GO:0007156; P:homophilic cell adhesion; IEA:InterPro.
DR   GO; GO:0007497; P:posterior midgut development; TAS:ProtInc.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   InterPro; IPR002126; Cadherin.
DR   InterPro; IPR015919; Cadherin-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR015777; Tyr_kinase_Ret_rcpt-like.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR016249; Tyr_prot_kinase_Ret_rcpt.
DR   Gene3D; G3DSA:2.60.40.60; Cadherin; 1.
DR   PANTHER; PTHR23256:SF245; RetRTK; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF00028; Cadherin; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000631; TyrPK_receptor_Ret; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00112; CA; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49313; Cadherin; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50268; CADHERIN_2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Chromosomal rearrangement;
KW   Complete proteome; Disease mutation; Glycoprotein;
KW   Hirschsprung disease; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     28       Potential.
FT   CHAIN        29   1114       Proto-oncogene tyrosine-protein kinase
FT                                receptor Ret.
FT                                /FTId=PRO_0000024450.
FT   TOPO_DOM     29    635       Extracellular (Potential).
FT   TRANSMEM    636    657       Helical; (Potential).
FT   TOPO_DOM    658   1114       Cytoplasmic (Potential).
FT   DOMAIN      168    272       Cadherin.
FT   DOMAIN      724   1016       Protein kinase.
FT   NP_BIND     730    738       ATP (By similarity).
FT   ACT_SITE    874    874       Proton acceptor (By similarity).
FT   BINDING     758    758       ATP (By similarity).
FT   SITE        712    713       Breakpoint for translocation to form
FT                                PCM1-RET; RET-CCDC6; RET-GOLGA5; RET-TIF1
FT                                and RET-TRIM33 oncogenes.
FT   MOD_RES     696    696       Phosphoserine.
FT   MOD_RES     806    806       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     809    809       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     900    900       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     905    905       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     981    981       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1015   1015       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1062   1062       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1090   1090       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1096   1096       Phosphotyrosine; by autocatalysis.
FT   CARBOHYD     98     98       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    151    151       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    199    199       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    336    336       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    343    343       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    361    361       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    367    367       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    377    377       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    394    394       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    468    468       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    554    554       N-linked (GlcNAc...) (Potential).
FT   VARIANT      20     20       P -> L (in HSCR; sporadic form).
FT                                /FTId=VAR_009459.
FT   VARIANT      32     32       S -> L (in HSCR; familial form).
FT                                /FTId=VAR_006295.
FT   VARIANT      40     40       L -> P (in HSCR).
FT                                /FTId=VAR_009492.
FT   VARIANT      64     64       P -> L (in HSCR; familial form).
FT                                /FTId=VAR_006296.
FT   VARIANT      67     67       R -> H (in CCHS).
FT                                /FTId=VAR_018153.
FT   VARIANT      77     77       R -> C (in HSCR).
FT                                /FTId=VAR_009460.
FT   VARIANT      93     93       G -> S (in HSCR; could be a rare
FT                                polymorphism).
FT                                /FTId=VAR_006297.
FT   VARIANT     114    114       R -> H (in CCHS).
FT                                /FTId=VAR_018154.
FT   VARIANT     142    142       C -> S (in HSCR; sporadic form).
FT                                /FTId=VAR_006298.
FT   VARIANT     145    145       V -> G (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035711.
FT   VARIANT     157    157       C -> Y (in HSCR; could be a
FT                                polymorphism).
FT                                /FTId=VAR_009461.
FT   VARIANT     163    163       R -> Q (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041762.
FT   VARIANT     174    174       F -> S (in HSCR; sporadic form).
FT                                /FTId=VAR_009462.
FT   VARIANT     180    180       R -> P (in HSCR; sporadic form).
FT                                /FTId=VAR_009463.
FT   VARIANT     197    197       C -> Y (in HSCR; sporadic form).
FT                                /FTId=VAR_009464.
FT   VARIANT     198    198       P -> T (in renal adysplasia; prevents
FT                                phosphorylation in response to GDNF).
FT                                /FTId=VAR_044392.
FT   VARIANT     231    231       R -> H (in HSCR; familial form).
FT                                /FTId=VAR_006299.
FT   VARIANT     251    251       E -> K (in HSCR; familial form).
FT                                /FTId=VAR_006300.
FT   VARIANT     278    278       T -> N (in dbSNP:rs35118262).
FT                                /FTId=VAR_041763.
FT   VARIANT     287    287       R -> Q (in HSCR; sporadic form).
FT                                /FTId=VAR_006301.
FT   VARIANT     292    292       V -> M (in dbSNP:rs34682185).
FT                                /FTId=VAR_041764.
FT   VARIANT     313    313       R -> Q (in HSCR; sporadic form).
FT                                /FTId=VAR_009465.
FT   VARIANT     330    330       R -> Q (in HSCR).
FT                                /FTId=VAR_006302.
FT   VARIANT     359    359       N -> K (in HSCR; could be a
FT                                polymorphism).
FT                                /FTId=VAR_009466.
FT   VARIANT     360    360       R -> W (in HSCR).
FT                                /FTId=VAR_009467.
FT   VARIANT     376    376       V -> A (in renal adysplasia;
FT                                constitutively phosphorylated; expressed
FT                                only the immature intracellular form).
FT                                /FTId=VAR_044393.
FT   VARIANT     393    393       F -> L (in HSCR; familial form).
FT                                /FTId=VAR_006303.
FT   VARIANT     394    394       N -> H (in renal adysplasia; prevents
FT                                phosphorylation in response to GDNF).
FT                                /FTId=VAR_044394.
FT   VARIANT     394    394       N -> K (in HSCR).
FT                                /FTId=VAR_009468.
FT   VARIANT     399    399       P -> L (in HSCR; sporadic form).
FT                                /FTId=VAR_006304.
FT   VARIANT     432    432       A -> E (in CCHS).
FT                                /FTId=VAR_018155.
FT   VARIANT     475    475       R -> Q (in HSCR; sporadic form).
FT                                /FTId=VAR_006305.
FT   VARIANT     489    489       D -> N (in dbSNP:rs9282834).
FT                                /FTId=VAR_018156.
FT   VARIANT     531    531       C -> CEEC (in MTC; familial form).
FT                                /FTId=VAR_009469.
FT   VARIANT     593    593       G -> E (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_035712.
FT   VARIANT     600    600       R -> Q (probably a rare polymorphism).
FT                                /FTId=VAR_008966.
FT   VARIANT     609    609       C -> G (in MEN2A).
FT                                /FTId=VAR_009470.
FT   VARIANT     609    609       C -> R (in MEN2A).
FT                                /FTId=VAR_009471.
FT   VARIANT     609    609       C -> W (in HSCR; familial form).
FT                                /FTId=VAR_006307.
FT   VARIANT     609    609       C -> Y (in MTC, MEN2A and HSCR; familial
FT                                and sporadic forms).
FT                                /FTId=VAR_006306.
FT   VARIANT     611    611       C -> G (in MTC; familial form).
FT                                /FTId=VAR_009472.
FT   VARIANT     611    611       C -> R (in MEN2A).
FT                                /FTId=VAR_009473.
FT   VARIANT     611    611       C -> S (in MEN2A).
FT                                /FTId=VAR_009474.
FT   VARIANT     611    611       C -> W (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006308.
FT   VARIANT     611    611       C -> Y (in MEN2A).
FT                                /FTId=VAR_006309.
FT   VARIANT     618    618       C -> F (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006312.
FT   VARIANT     618    618       C -> G (in MEN2A).
FT                                /FTId=VAR_006310.
FT   VARIANT     618    618       C -> R (in MEN2A, MTC and HSCR).
FT                                /FTId=VAR_006311.
FT   VARIANT     618    618       C -> S (in MEN2A, HSCR and MTC; familial
FT                                and sporadic forms).
FT                                /FTId=VAR_006313.
FT   VARIANT     618    618       C -> Y (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006314.
FT   VARIANT     620    620       C -> F (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006318.
FT   VARIANT     620    620       C -> G (in MEN2A and MTC; familial and
FT                                sporadic forms).
FT                                /FTId=VAR_006315.
FT   VARIANT     620    620       C -> R (in MEN2A, MTC and HSCR; familial
FT                                and sporadic forms).
FT                                /FTId=VAR_006316.
FT   VARIANT     620    620       C -> S (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006317.
FT   VARIANT     620    620       C -> W (in MEN2A and HSCR).
FT                                /FTId=VAR_009475.
FT   VARIANT     620    620       C -> Y (in MEN2A).
FT                                /FTId=VAR_006319.
FT   VARIANT     626    626       Q -> K (in HSCR; sporadic form).
FT                                /FTId=VAR_009476.
FT   VARIANT     630    630       C -> F (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_006320.
FT   VARIANT     630    630       C -> S (in MTC; sporadic form).
FT                                /FTId=VAR_009477.
FT   VARIANT     630    630       C -> Y (in MTC; familial and sporadic
FT                                forms).
FT                                /FTId=VAR_009478.
FT   VARIANT     631    631       D -> G (in thyroid carcinoma; somatic
FT                                mutation).
FT                                /FTId=VAR_006321.
FT   VARIANT     632    634       ELC -> DVR (in MEN2A).
FT                                /FTId=VAR_006322.
FT   VARIANT     634    635       CR -> WG (in MEN2A).
FT                                /FTId=VAR_006329.
FT   VARIANT     634    634       C -> CHELC (in MEN2A).
FT                                /FTId=VAR_009479.
FT   VARIANT     634    634       C -> F (in MEN2A and pheochromocytoma).
FT                                /FTId=VAR_006324.
FT   VARIANT     634    634       C -> G (in MEN2A and pheochromocytoma).
FT                                /FTId=VAR_006323.
FT   VARIANT     634    634       C -> R (in MEN2A, pheochromocytoma and
FT                                MTC; familial form; also found as somatic
FT                                mutation in a sporadic thyroid
FT                                carcinoma).
FT                                /FTId=VAR_006326.
FT   VARIANT     634    634       C -> S (in MEN2A, pheochromocytoma and
FT                                MTC; familial form).
FT                                /FTId=VAR_006327.
FT   VARIANT     634    634       C -> W (in MEN2A, pheochromocytoma and
FT                                MTC; familial form).
FT                                /FTId=VAR_006328.
FT   VARIANT     634    634       C -> Y (in MEN2A, pheochromocytoma and
FT                                MTC; familial form).
FT                                /FTId=VAR_006325.
FT   VARIANT     636    636       T -> TCRT (in MEN2A).
FT                                /FTId=VAR_006330.
FT   VARIANT     639    639       A -> G (in MTC; sporadic form).
FT                                /FTId=VAR_012743.
FT   VARIANT     640    640       A -> G (in MEN2A).
FT                                /FTId=VAR_009480.
FT   VARIANT     641    641       A -> G (in MTC; sporadic form).
FT                                /FTId=VAR_012744.
FT   VARIANT     690    690       S -> P (in HSCR; sporadic form).
FT                                /FTId=VAR_006331.
FT   VARIANT     691    691       G -> S (in dbSNP:rs1799939).
FT                                /FTId=VAR_006332.
FT   VARIANT     749    749       R -> T (in dbSNP:rs34288963).
FT                                /FTId=VAR_041765.
FT   VARIANT     762    762       E -> Q (in HSCR; sporadic form).
FT                                /FTId=VAR_009481.
FT   VARIANT     765    765       S -> P (in HSCR).
FT                                /FTId=VAR_009493.
FT   VARIANT     767    767       S -> R (in HSCR; sporadic form).
FT                                /FTId=VAR_006334.
FT   VARIANT     768    768       E -> D (in MTC; familial and sporadic
FT                                forms).
FT                                /FTId=VAR_006335.
FT   VARIANT     778    778       V -> I (in renal adysplasia;
FT                                constitutively phosphorylated).
FT                                /FTId=VAR_044395.
FT   VARIANT     790    790       L -> F (in MEN2A and MTC; familial form).
FT                                /FTId=VAR_009482.
FT   VARIANT     791    791       Y -> F (in HSCR, pheochromocytoma, MTC
FT                                and MEN2A; familial form).
FT                                /FTId=VAR_009483.
FT   VARIANT     804    804       V -> L (in MTC; familial form).
FT                                /FTId=VAR_006336.
FT   VARIANT     804    804       V -> M (in MTC; familial form).
FT                                /FTId=VAR_006337.
FT   VARIANT     813    813       R -> Q (in HSCR; sporadic form).
FT                                /FTId=VAR_009484.
FT   VARIANT     826    826       Y -> S (in dbSNP:rs34617196).
FT                                /FTId=VAR_041766.
FT   VARIANT     844    844       R -> L (in MTC; familial form;
FT                                dbSNP:rs55947360).
FT                                /FTId=VAR_011582.
FT   VARIANT     873    873       R -> Q (in HSCR; sporadic form).
FT                                /FTId=VAR_006338.
FT   VARIANT     883    883       A -> F (in MEN2B; somatic mutation in
FT                                sporadic medullary thyroid carcinoma;
FT                                requires 2 nucleotide substitutions).
FT                                /FTId=VAR_009485.
FT   VARIANT     891    891       S -> A (in MTC; familial form).
FT                                /FTId=VAR_009486.
FT   VARIANT     893    893       F -> L (in HSCR; sporadic form).
FT                                /FTId=VAR_006339.
FT   VARIANT     894    894       G -> S (in renal adysplasia;
FT                                constitutively phosphorylated; expressed
FT                                only the immature intracellular form).
FT                                /FTId=VAR_044396.
FT   VARIANT     897    897       R -> Q (in HSCR; sporadic form).
FT                                /FTId=VAR_006340.
FT   VARIANT     907    907       K -> E (in HSCR; sporadic form).
FT                                /FTId=VAR_006341.
FT   VARIANT     918    918       M -> T (in renal adysplasia, MEN2B and
FT                                MTC; sporadic form; somatic mutation).
FT                                /FTId=VAR_006342.
FT   VARIANT     921    921       E -> K (in HSCR; sporadic form).
FT                                /FTId=VAR_006343.
FT   VARIANT     922    922       S -> F (in MTC; sporadic form).
FT                                /FTId=VAR_012745.
FT   VARIANT     922    922       S -> Y (rare polymorphism).
FT                                /FTId=VAR_009487.
FT   VARIANT     946    946       T -> M (in MEN2B and MTC; familial form).
FT                                /FTId=VAR_006345.
FT   VARIANT     972    972       R -> G (in HSCR; familial form).
FT                                /FTId=VAR_006346.
FT   VARIANT     973    973       P -> L (in HSCR; familial form).
FT                                /FTId=VAR_006347.
FT   VARIANT     980    980       M -> T (in HSCR; sporadic form).
FT                                /FTId=VAR_006348.
FT   VARIANT     982    982       R -> C (in dbSNP:rs17158558).
FT                                /FTId=VAR_006349.
FT   VARIANT    1039   1039       P -> L (in CCHS; with colonic
FT                                aganglionosis).
FT                                /FTId=VAR_018157.
FT   VARIANT    1039   1039       P -> Q.
FT                                /FTId=VAR_009488.
FT   VARIANT    1049   1049       P -> L (in renal adysplasia; prevents
FT                                phosphorylation in response to GDNF).
FT                                /FTId=VAR_044397.
FT   VARIANT    1059   1059       Missing (in HSCR).
FT                                /FTId=VAR_009489.
FT   VARIANT    1061   1061       L -> P (in HSCR).
FT                                /FTId=VAR_009490.
FT   VARIANT    1064   1064       M -> T (in HSCR; familial form).
FT                                /FTId=VAR_009491.
FT   VARIANT    1067   1067       P -> S (in renal adysplasia; prevents
FT                                phosphorylation in response to GDNF).
FT                                /FTId=VAR_044398.
FT   VARIANT    1112   1112       F -> Y (in a bladder transitional cell
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041767.
FT   CONFLICT    647    647       I -> V (in Ref. 3; AAA36786).
FT   CONFLICT    750    750       A -> G (in Ref. 6; AAA36524).
FT   CONFLICT    904    904       S -> P (in Ref. 3; AAA36786).
FT   HELIX       705    710
FT   TURN        715    717
FT   HELIX       721    723
FT   STRAND      724    732
FT   STRAND      734    744
FT   HELIX       746    748
FT   STRAND      750    759
FT   HELIX       766    779
FT   STRAND      790    794
FT   STRAND      796    799
FT   STRAND      801    805
FT   HELIX       812    818
FT   TURN        819    821
FT   HELIX       848    867
FT   HELIX       877    879
FT   STRAND      880    883
FT   TURN        884    886
FT   STRAND      887    890
FT   TURN        900    902
FT   HELIX       915    917
FT   HELIX       920    925
FT   HELIX       930    945
FT   HELIX       957    959
FT   HELIX       960    965
FT   HELIX       978    987
FT   HELIX       992    994
FT   HELIX       998   1010
SQ   SEQUENCE   1114 AA;  124319 MW;  A3DA0CE01A19A441 CRC64;
     MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP
     EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT
     VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR
     PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV
     AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD
     ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR
     NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA
     QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE
     LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR
     CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR
     GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY
     HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP
     RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK
     QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH
     PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY
     EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL
     FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA
     STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGMSDPNWP GESPVPLTRA
     DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS
//
